Valbiotis Publishes New Study on TOTUM-448 for MASLD

Valbiotis has announced the publication of a new study on TOTUM-448, an active substance aimed at treating metabolic liver disease (MASLD), in the international journal Scientific Reports. This is the third publication on TOTUM-448, marking the first to present human study results.

The research highlights the bioavailability of TOTUM-448 and its mode of action, showing a reduction in intracellular lipids and inflammation in liver cells. Conducted with Clinic'n'Cell and other research partners, this study adds to Valbiotis' 15 scientific publications, bolstering the firm's ongoing research efforts.

TOTUM-448 will expand the ValbiotisPRO® range, leveraging multi-channel marketing strategies in France, Asia, and the Middle East. As Valbiotis proceeds with its Cardio-Liver clinical study in Canada, more publications are expected in 2026 on its effects and modes of action.